Mitsuhiro Furuta1,2, Junichiro Watanabe3, Takeshi Aramaki4, Akifumi Notsu5, Hirofumi Yasui2. 1. Division of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan. 2. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. 3. Division of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan j.watanabe@scchr.jp. 4. Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan. 5. Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Abstract
BACKGROUND/AIM: Hepatic arterial infusion chemotherapy (HAIC) is a treatment option for metastatic breast cancer (MBC) patients with extensive liver metastasis (LM); however, the appropriate regimen and the treatment effects have not been discussed. The aim of this study is to evaluate the efficacy and safety of HAIC with the 5-FU, epirubicin, and mitomycin-C (FEM) regimen. PATIENTS AND METHODS: We reviewed MBC patients with critical LM who were resistant to standard systemic chemotherapies and had received HAIC with an FEM regimen. RESULTS: We identified 57 patients who received HAIC between 2003 and 2017. The patient characteristics were as follows: i) median age=56 (30-80), and ii) Eastern Cooperative Oncology Group Performance Status, 0/1/2=43/11/3. The median number of LMs was 8 (range 1 to ≥20), the median diameter of LM was 5.2 cm (range=1.6 to 20.1). The median overall survival from the initiation of HAIC was 11.3 months (95% confidence interval=8.5-15.6). The objective response rate of LM was 63%. CONCLUSION: HAIC with an FEM regimen is an effective salvage treatment for MBC patients with advanced LM. Copyright
BACKGROUND/AIM: Hepatic arterial infusion chemotherapy (HAIC) is a treatment option for metastatic breast cancer (MBC) patients with extensive liver metastasis (LM); however, the appropriate regimen and the treatment effects have not been discussed. The aim of this study is to evaluate the efficacy and safety of HAIC with the 5-FU, epirubicin, and mitomycin-C (FEM) regimen. PATIENTS AND METHODS: We reviewed MBC patients with critical LM who were resistant to standard systemic chemotherapies and had received HAIC with an FEM regimen. RESULTS: We identified 57 patients who received HAIC between 2003 and 2017. The patient characteristics were as follows: i) median age=56 (30-80), and ii) Eastern Cooperative Oncology Group Performance Status, 0/1/2=43/11/3. The median number of LMs was 8 (range 1 to ≥20), the median diameter of LM was 5.2 cm (range=1.6 to 20.1). The median overall survival from the initiation of HAIC was 11.3 months (95% confidence interval=8.5-15.6). The objective response rate of LM was 63%. CONCLUSION: HAIC with an FEM regimen is an effective salvage treatment for MBC patients with advanced LM. Copyright
Authors: Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Nadia Harbeck; Jutta Engel Journal: J Cancer Res Clin Oncol Date: 2017-04-20 Impact factor: 4.553
Authors: Ki-Tae Hwang; Jongjin Kim; Jiwoong Jung; Ji Hyun Chang; Young Jun Chai; So Won Oh; Sohee Oh; Young A Kim; Sung Bae Park; Kyu Ri Hwang Journal: Clin Cancer Res Date: 2018-12-17 Impact factor: 12.531
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: Mitra Tewes; Michael Wilhelm Peis; Simon Bogner; Jens M Theysohn; Marcus Paul Reinboldt; Martin Schuler; Anja Welt Journal: J Cancer Res Clin Oncol Date: 2017-06-23 Impact factor: 4.553